157 related articles for article (PubMed ID: 19005564)
1. Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z; Feng J; Buzin CH; Sommer SS
PLoS One; 2008; 3(11):e3714. PubMed ID: 19005564
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency.
Hill KA; Wang J; Farwell KD; Scaringe WA; Sommer SS
Mutat Res; 2004 Oct; 554(1-2):223-40. PubMed ID: 15450421
[TBL] [Abstract][Full Text] [Related]
3. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.
Chen Z; Feng J; Saldivar JS; Gu D; Bockholt A; Sommer SS
Oncogene; 2008 Jul; 27(31):4336-43. PubMed ID: 18372921
[TBL] [Abstract][Full Text] [Related]
4. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort.
Scoccianti C; Vesin A; Martel G; Olivier M; Brambilla E; Timsit JF; Tavecchio L; Brambilla C; Field JK; Hainaut P;
Eur Respir J; 2012 Jul; 40(1):177-84. PubMed ID: 22267755
[TBL] [Abstract][Full Text] [Related]
6. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
7. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
[TBL] [Abstract][Full Text] [Related]
8. Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events.
Buettner VL; Hill KA; Scaringe WA; Sommer SS
Mutat Res; 2000 Sep; 452(2):219-29. PubMed ID: 11024481
[TBL] [Abstract][Full Text] [Related]
9. Evidence for mutation showers.
Wang J; Gonzalez KD; Scaringe WA; Tsai K; Liu N; Gu D; Li W; Hill KA; Sommer SS
Proc Natl Acad Sci U S A; 2007 May; 104(20):8403-8. PubMed ID: 17485671
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
12. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
[TBL] [Abstract][Full Text] [Related]
14. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
Zhang W; Stabile LP; Keohavong P; Romkes M; Grandis JR; Traynor AM; Siegfried JM
J Thorac Oncol; 2006 Sep; 1(7):635-47. PubMed ID: 17409930
[TBL] [Abstract][Full Text] [Related]
15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
17. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
18. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
20. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.
Kawaguchi T; Koh Y; Ando M; Ito N; Takeo S; Adachi H; Tagawa T; Kakegawa S; Yamashita M; Kataoka K; Ichinose Y; Takeuchi Y; Serizawa M; Tamiya A; Shimizu S; Yoshimoto N; Kubo A; Isa S; Saka H; Matsumura A
J Clin Oncol; 2016 Jul; 34(19):2247-57. PubMed ID: 27161973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]